Not all products are created equal
It improves the chances of a steady amount of the medicine being absorbed into your system with each dose
These symptoms are usually temporary and improve as the body adjusts
The estimated mean change in body weight at week 68 was 20.4% with CagriSema versus 3.0% with placebo (a difference of about 17 percentage points), and more CagriSema participants reached weight-loss thresholds of 5%, 20%, 25%, and 30% than placebo
Tirzepatide has shown promising cardiovascular and heart failure benefits, including positive outcomes in people with obesity and heart failure with preserved ejection fraction
Cardiometabolic improvements across published trials include reductions in blood pressure, triglycerides, LDL-cholesterol, HbA1c, and fasting glucose